C - Chemistry – Metallurgy – 12 – N
Patent
C - Chemistry, Metallurgy
12
N
C12N 7/00 (2006.01) A61K 31/70 (2006.01) A61K 35/12 (2006.01) A61K 48/00 (2006.01) C12M 3/00 (2006.01) C12M 3/06 (2006.01) C12N 5/00 (2006.01) C12N 5/10 (2006.01) C12N 9/78 (2006.01) C12N 15/86 (2006.01) C12N 15/867 (2006.01)
Patent
CA 2098510
2098510 9210564 PCTABS00013 This invention provides improved methods for producing high titers of recombinant viral vectors by culturing producer cells in a hollow fiber bioreactor. The titer of virus in the extra fiber space (EFS) of the hollow fiber bioreactor is sufficient to transduce target cells at a multiplicity of infection sufficient to render the transduced target cells useful for genetic therapy. In a preferred embodiment, target cells are transduced with the EFS medium from a hollow fiber bioreactor in which a producer cell line, which releases packaged retroviral vectors into the EFS, has been cultured. Lymphocytes derived from an adenosine deaminase (ADA)-deficient individual that have been transduced with EFS medium that contains retroviral vectors that include RNA that encodes ADA, express ADA at a rate comparable to that of cells from an individual who does not have ADA deficiency.
Blaese R. Michael
Culver Kenneth W.
Knazek Richard A.
Cellco Inc.
Swabey Ogilvy Renault
U.s. Departm Ent Of Commerce The United States Of America Represented By The Secretary
LandOfFree
Sustained and continuous production of high titers of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Sustained and continuous production of high titers of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sustained and continuous production of high titers of... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1362029